Drugs / Abelacimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04755283 | Feb 2021 → Feb 2024 overdue | atrial fibrillation, stroke disorder | Anthos Therapeutics, Inc. | Active not recruiting | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT05712200 | Dec 2022 → Dec 2027 expected | atrial fibrillation | Anthos Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05171075 | Sep 2022 → Apr 2026 | pulmonary embolism, venous thromboembolism | Anthos Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT05171049 | May 2022 → Feb 2026 | pulmonary embolism, venous thromboembolism | Anthos Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abelacimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05171075 ↗ |
| Action | Inhibit | “binds to the inactive form of factor XI and blocks its activation” PMID 39842011 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “Abelacimab is a fully human monoclonal antibody” PMID 39842011 ↗ Jan 2025 |
| Route | Subcutaneous | “subcutaneous injection of abelacimab” PMID 39842011 ↗ Jan 2025 |
| Target | F11 | “binds to the inactive form of factor XI and blocks its activation” PMID 39842011 ↗ Jan 2025 |